
HF Incidence: 2023 female Baseline 0.14 Lifestyle Outreach Polypill 0.12 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -70_to_74 -75_to_79 -65_to_69 90_to_94 35_to_39 40_to_44 55_to_59 85_to_89 25_to_29 30_to_34 45_to_49 50_to_54 60_to_64 80_to_84

HF Incidence: 2024 female Baseline 0.14 Lifestyle Outreach 0.12 Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -70_to_74 -75_to_79 -65_to_69 90_to_94 35_to_39 40_to_44 85_to_89 25_to_29 30_to_34 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84

HF Incidence: 2025 female Baseline 0.14 Lifestyle Outreach 0.12 Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -70_to_74 -65_to_69 90_to_94 35_to_39 40_to_44 85_to_89 25_to_29 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84

HF Incidence: 2026 female Baseline 0.14 Lifestyle Outreach 0.12 Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -70_to_74 -65_to_69 90_to_94 35_to_39 40_to_44 85_to_89 25_to_29 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84




HF Incidence: 2028 female Baseline Lifestyle 0.12 Outreach Polypill 0.10 0.08 0.06 0.04 0.02 0.00 65_to_69 -95_plus -70_to_74 -90_to_94 35_to_39 40_to_44 85_to_89 25_to_29 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84

HF Incidence: 2029 female Baseline 0.14 Lifestyle Outreach 0.12 Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -70_to_74 -75_to_79 -65_to_69 90_to_94 35_to_39 40_to_44 55_to_59 85_to_89 25_to_29 30_to_34 45_to_49 50_to_54 60_to_64 80_to_84

HF Incidence: 2030 female 0.14 Baseline Lifestyle 0.12 Outreach Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -60_to_64 -65_to_69 90_to_94 35_to_39 40_to_44 70_to_74 85_to_89 25_to_29 45_to_49 50_to_54 55_to_59 80_to_84

HF Incidence: 2031 female Baseline 0.14 Lifestyle Outreach 0.12 Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -70_to_74 -75_to_79 -40_to_44 65_to_69 90_to_94 35_to_39 45_to_49 85_to_89 25_to_29 50_to_54 55_to_59 60_to_64 80_to_84

HF Incidence: 2032 female Baseline 0.14 Lifestyle Outreach 0.12 Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -70_to_74 -65_to_69 90_to_94 35_to_39 40_to_44 85_to_89 25_to_29 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84



HF Incidence: 2034 female 0.14 Baseline Lifestyle 0.12 Outreach Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -65_to_69 70_to_74 90_to_94 25_to_29 35_to_39 40_to_44 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84 85_to_89

HF Incidence: 2035 female 0.14 Baseline Lifestyle Outreach 0.12 Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -70_to_74 -65_to_69 90_to_94 35_to_39 40_to_44 85_to_89 25_to_29 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84

HF Incidence: 2036 female Baseline 0.12 Lifestyle Outreach Polypill 0.10 0.08 0.06 0.04 0.02 0.00 65_to_69 -95_plus -70_to_74 -75_to_79 -90_to_94 35_to_39 40_to_44 85_to_89 25_to_29 30_to_34 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84

HF Incidence: 2037 female Baseline Lifestyle 0.12 Outreach Polypill 0.10 0.08 0.06 0.04 0.02 0.00 70_to_74 -95_plus -45_to_49 -35_to_39 60_to_64 75_to_79 85_to_89 25_to_29 30_to_34 50_to_54 55_to_59 80_to_84

HF Incidence: 2038 female Baseline Lifestyle 0.12 Outreach Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -70_to_74 -65_to_69 90_to_94 35_to_39 85_to_89 25_to_29 40_to_44 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84

HF Incidence: 2039 female Baseline Lifestyle 0.12 Outreach Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -70_to_74 -65_to_69 90_to_94 35_to_39 40_to_44 85_to_89 25_to_29 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84

HF Incidence: 2040 female 0.14 Baseline Lifestyle 0.12 Outreach Polypill 0.10 0.08 0.06 0.04 0.02 0.00 95_plus -65_to_69 70_to_74 90_to_94 25_to_29 35_to_39 40_to_44 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84 85_to_89

